- Durata Therapeutics (DRTX) says the FDA has approved its Dalvance antibiotic for the treatment of patients with acute bacterial skin and skin structure infections.
- Dalvance is the first drug with the qualified infectious disease product designation to receive FDA approval.
- A March FDA advisory panel approval also had given a favorable review to a rival product from Cubist Pharmaceuticals (CBST); the FDA is set to rule on the CBST drug shortly.
- DRTX shares halted.
From other sites
at Benzinga.com (Dec 31, 2014)
at CNBC.com (Oct 6, 2014)
at MarketWatch.com (Oct 6, 2014)
at CNBC.com (Aug 4, 2014)
at MarketWatch.com (May 27, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs